<DOC>
	<DOCNO>NCT01498887</DOCNO>
	<brief_summary>This study ass efficacy fingolimod patient short duration relapsing-remitting multiple sclerosis previously treat disease-modifying therapy ( DMTs ) , versus patient disease duration previously receive first-line Disease Modifying Therapies .</brief_summary>
	<brief_title>Efficacy Fingolimod de Novo Patients Versus Fingolimod Patients Previously Treated With First Line Disease Modifying Therapy</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Patients diagnose multiple sclerosis , accord 2010 revise McDonald criterion , relapsingremitting course , least 9 T2 lesion consistent disease , disease duration great equal one year less equal five year . Patients least two relapse past two year Expanded Disability Status Scale score 0 3.5 , inclusive . Patients Treatment na√Øve : patient never treat Disease Modifying Therapy Previously treat firstline Disease Modifying Therapy Patients receive treatment : Fingolimod time ( e.g . participation fingolimod clinical trial ) , Immunosuppressant drug azathioprine methotrexate time ; Immunoglobulins past 6 month . Monoclonal antibody include natalizumab , Cladribine , cyclophosphamide mitoxantrone , time . Other protocol define inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing Remitting Multiple Sclerosis</keyword>
	<keyword>Fingolimod</keyword>
	<keyword>Early multiple sclerosis</keyword>
	<keyword>Naive patient</keyword>
</DOC>